TRIM21 and systemic lupus erythematosus: Animal model studies revealed that TRIM21-/- mice developed SLE-related clinical manifestations after skin lesions and abnormalities in the IL-23-Th17 pathway, which triggered tissue inflammation and systemic autoimmunity, suggesting that TRIM21 protects the organism by negatively regulating pro-inflammatory factor production in SLE (33).